Scientists, engineers, and chemists who built this before AI was a buzzword.

Computational drug design across small-molecule, protein, and RNA modalities. MFE (UC Berkeley Haas), MS Artificial Intelligence (Georgia Tech), PhD Computational Biology (UAB) with structural-biology postdoc. 18+ years in computational drug design. Former Senior Investigator at the Bill & Melinda Gates Foundation. Former Director & Senior Scientist at UAB Medicine.

15+ years in biologics discovery across immuno-oncology, autoimmune disease, and neurodegeneration. Leads R&D strategy at Ainnocence. Previously Executive Director & Head of Biologics at SciNeuro Pharmaceuticals, Head of Preclinical Pipeline at Georgiamune, senior roles at OncoC4, NovaRock, and Precigen. Co-founder & CTO of ElAb Bio. Inventor on 8 patents; author in Blood, J. Immunology, Nature Immunology. PhD, Medical University of South Carolina.

Advanced drug delivery, regenerative biomaterials, and biological model development. Associate Director of Advanced Drug Delivery & Regenerative Biomaterials at Stanford University, developing novel drugs and materials to improve human health. Co-founder of ETTA Biotech (therapeutic delivery platforms). Previously at OpenAI, working on biological model tuning. Postdoctoral training with Dr. Tony Wyss-Coray and Dr. Carolyn Bertozzi at Stanford on protein factors in brain aging and bioorthogonal chemistry (Wu Tsai Neurosciences Institute Interdisciplinary Scholar). PhD in Molecular Biophysics with Dr. Josep Rizo at UT Southwestern, where he determined a structural model of the synaptotagmin–SNARE complex underlying rapid neurotransmitter release. BS Biochemistry & BA Chemistry, NC State University, with early research at the NIH–National Institute of Environmental Health Sciences.

4 years AI/ML platform engineering, industry. MS Data Science, University of Southern California. Lead maintainer of SentinusAI's model-serving and training infrastructure.

10 years of research and product development. Deep expertise in medical ML/AI for drug discovery. MS Biomedical Engineering, Columbia University.

UC Davis (Biotechnology), pursuing dual masters in Molecular Biology and Bioinformatics. Former SRA/Scientist at Retro Biosciences (stem-cell reprogramming, longevity) and Sangamo Therapeutics (allogeneic cell therapy, zinc-finger gene editing).

6 years of commercial experience across account management, executive support, and marketing. Runs internal operations and partner coordination through the licensing lifecycle.

Coordinates program timelines, partner deliverables, and cross-functional execution across Ainnocence's biologics pipeline. Research background with primary human stem cells and hematologic malignancies. MS Biotechnology, Johns Hopkins University.

William K. Bowes Jr. Distinguished Investigator and Professor of Pharmaceutical Chemistry at UCSF; Senior Investigator at the Gladstone Institute of Cardiovascular Disease. Scientific co-founder of Fate Therapeutics, Tenaya Therapeutics, Retro Biosciences, and Stemgent. Pioneer in chemical approaches to stem cell biology and cellular reprogramming, with seminal contributions to induced pluripotency and chemically-defined cell-fate control. 300+ peer-reviewed publications; one of the most-cited chemical biologists of his generation. PhD, The Scripps Research Institute; BS Chemistry, Caltech.

Boyd Professor of Louisiana State University (LSU's highest faculty rank, awarded 2025); Director, Metabolism and Body Composition Laboratory, Pennington Biomedical Research Center. Former Executive Director of Pennington Biomedical. Former Executive Director of Clinical Sciences (Metabolism) and Global Director of Scientific Affairs (Obesity) at Merck & Co. Former Professor of Medicine at Columbia University and Deputy Director of the New York Obesity Research Center. Amazon Scholar (2021–2023), collaborating on digital health innovations. Past president of The Obesity Society, the American Society of Clinical Nutrition, and the American Society of Parenteral and Enteral Nutrition. Member, U.S. Dietary Guidelines Advisory Committee (2020). Internationally recognized authority on body composition, skeletal muscle, obesity, and cancer cachexia. 500+ peer-reviewed publications. MD, Mount Sinai School of Medicine.

Professor Emeritus of Electrical & Computer Engineering, University of Alabama at Birmingham, where he held the Wallace R. Bunn Endowed Chair. Former Director of the Software Engineering Research Center, UT Austin. Co-director, Integrated Systems Center. Co-founder of the Society for Design and Process Science (SDPS). Decades of research across software engineering, systems design, and process science; multiple editorial and advisory roles. Collaborator on computational-biology work with the Ainnocence founding team. PhD Computer Science, Texas A&M University.

20+ years preclinical drug discovery across oncology, immunology, neuroscience, and metabolic disease. Former Associate Principal Scientist at Merck & Co. (Schering-Plough), advanced two compounds to clinical trials including the first-in-class ERK inhibitor MK-8353. Deep expertise in ADC/bsADC and degrader-antibody conjugate (DAC) design. PhD Organic Chemistry, UC Irvine.